-
Scientific rationale
Breast cancer research has been the frontrunner in many fields of cancer research: epidemiology, life-style and genetic risk factors, secondary prevention, conservative surgery, molecular classification, curative adjuvant therapies, neoadjuvant treatments, targeted agents, survival prolongation in advanced stages. Thanks to this knowledge, today many breast cancers can be prevented, most can be diagnosed at early stages and cured and the minority of patients at advanced stages can still enjoy a significant survival with a reasonable quality of life.
As a consequence of these major improvements, the bar of research and clinical excellence for breast cancer has raised even more.
New prognostic and predictive biomarkers are available, need to be validated and to be implemented in trial design and clinical practice. Risk-adapted surgery and radiation therapy allow for less and less invasive procedures. Multiple effective adjuvant therapies in the different molecular breast cancer subtypes, require a more precise definition of risk and predictivity of drug efficacy, to allow for a rational de-escalation or escalation of curative treatments. The impressive advances in the treatment of advanced breast cancers, envisage the possibility of cure with a multimodality approach for some patients and guarantee a prolonged survival for most of them with a rational sequencing of treatments.
The 20th AIBCC in Padova, will allow to sum up the most recent biological and clinical achievements and to allow an open and friendly discussion of clinical cases among key opinion leaders and participants.Visit the website https://meettheprofessor.accmed.org/
-
Programme
Questo evento formativo si terrà esclusivamente in forma residenziale10.30 Introduction to the Conference Pierfranco Conte, Valentina Guarneri, Philip Poortmans, Aleix Prat SESSION I – EVOLVING KNOWLEDGE OF BREAST CANCER BIOLOGY: IMPLICATIONS FOR STAGING, PROGNOSIS AND PREDICTION Chairpersons: Maria Vittoria Dieci, Hesham Ahmed Gaballah Elghazaly 11.00 Gene expression tools in early-stage HR+/HER2- breast cancer: questioning the grey areas Alberto Zambelli 11.20 The immune system and breast cancer: TNBC and beyond Marleen Kok 11.40 DNA NGS-based biomarkers to inform treatment sequence in advanced breast cancer Mafalda Oliveira 12.00 Tackling the biological diversity in HER2-positive breast cancer: clinical implications Aleix Prat 12.20 Discussion 12.50 Lunch SESSION II – LOCOREGIONAL Tx AND GENOMICS Chairpersons: Jacek Jassem, Eleftherios Mamounas 14.00 Surgery of the axilla: is less always more? Oreste Davide Gentilini 14.20 Navigating RT options according to genetic risck profiles Philip Poortmans 14.40 Evolving concepts in genetic testing: finding the balance Angela Toss 15.00 Discussion SESSION III – EARLY BREAST CANCER: NEOADJUVANT AND POST-NEOADJUVANT THERAPY Chairpersons:Pierfranco Conte, Sibylle Loibl 15.30 Modulation of neoadjuvant and post-neoadjuvant treatment in HER2+ (pert, TDM1, neratinib, trials) 15.50 Modulation of neoadjuvant and post-neoadjuvant treatment in TNBC (IO, PARPi, capeitabine) Pierfranco Conte 16.10 Indication to and modalities of neoadjuvant Tx in HR+HER2- BC Valentina Guarneri 16.30 Discussion 17.00 Adjourn 17.15 Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2024 17.30 Lecture of the Awardee
Boosting Academic Research To Meet The Unmet Needs in Breastc Cancer Therapy"Claudio Vernieri 18.00 Adjourn SESSION IV – EARLY BREAST CANCER Chairpersons: Valentina Guarneri, Aleix Prat 9.00 Enhancing efficacy of hormonal therapy in early breast cancer (bisphosphonates, extended, CDK4/6i, SERDs, PARPi…) Stephen Johnston 9.20 Optimizing treatment for small tumors depending on local treatments Hope Rugo 9.40 The challenge of lobular breast cancer Maria Vittoria Dieci 10.00 Discussion 10.30 Coffee break 11.00 Clinical Multidisciplinary Shooting Session 1 – Early Breast Cancer Bettina Borisch, Hesham Ahmed Gaballah Elghazaly, Massimo Ferrucci, Oreste Davide Gentilini, Jacek Jassem, Eleftherios Mamounas, Fedro Alessandro Peccatori, Philip Poortmans, Aleix Prat 12.30 Lunch SESSION V – METASTATIC BREAST CANCER: CONSOLIDATED AND NEW ALGORITHMS Chairpersons: Piefranco Conte, Sandra Swain M. 13.30 HR+ disease
Current algorithm: Claudio Vernieri
Adapting the algorithm in a contemporary scenario: Carmen Criscitiello14.00 HER2+ disease
Current algorithm: Federica Miglietta
Treatment sequences in new emerging populations: Sandra Swain14.30 Triple negative disease
Current algorithm: Gaia Griguolo
Treatment sequences in new emerging populations: Hope Rugo15.00 Discussion 15.20 Clinical Multidisciplinary Shooting Session 2 – Advanced Breast Cancer Pierfranco Conte, Hesham Ahmed Gaballah Elghazaly, Oreste Davide Gentilini, Stephen Johnston, Philip Poortmans, Hope Rugo, Sandra Swain M 16.40 Take home messages and adjourn Pierfranco Conte, Valentina Guarneri, Philip Poortmans, Aleix Prat
-
Faculty
Pierfranco Conte Venezia Valentina Guarneri Padova Philip Poortmans Wolrijk-antwerp (Belgio) Aleix Prat Barcellona (Spagna) Bettina Borisch Geneva (Svizzera) Carmen Criscitiello Milano Maria Vittoria Dieci Padova Hesham Ahmed Gaballah Elghazaly Cairo (Egitto) Massimo Ferrucci Padova Oreste Davide Gentilini Milano Gaia Griguolo Padova Johannes Holtschmidt Frankfurt (Germania) Jacek Jassem Gdansk (Polonia) Stephen Johnston Londra (Regno Unito) Marleen Kok Amsterdam (Paesi Bassi) Eleftherios Mamounas Orlando - Florida (Stati Uniti D'America) Federica Miglietta Padova Mafalda Oliveira Barcellona (Spagna) Fedro Alessandro Peccatori Milano Hope Rugo San Francisco (Stati Uniti D'America) Sandra Swain M Washington (Stati Uniti D'America) Angela Toss Modena Claudio Vernieri Milano Alberto Zambelli Rozzano (MI) -
How to participate the meeting
Enrollment in the course can only be done through the online procedure, no new registrations will be accepted at the congress venue.
-
Registration
Participation registration fees
- Quota di partecipazione intera € 120.00
- Quota di iscrizione per specializzandi € 80.00
- Quota di iscrizione soci aiom € 80.00
For eligibility criteria and other information on reduced fees (if applicable), contact info.bologna@accmed.org.
To participate in the event, it is necessary to complete the registration procedure (including payment of the applicable fee) by 19/10/2024. Payment can be made online exclusively with Credit Cards or Paypal.
If the minimum number of participants is not reached, the Academy reserves the right to cancel the activity. In this case, Accademia will proceed with the appropriate communication and full refund of the participation fees.
In case of withdrawal, please inform AccMed promptly. If the waiver occurs within the 10th day prior to the start date of the event, the amount paid will be returned with the deduction of 30%. If the waiver occurs after that deadline, no reimbursement will be provided.
-
CME Instructions
To obtain CME credits, users must meet the following requirements:
- Their declared profession/specialization must correspond to those accredited for CME.
- They must attend at least 90% of the course.
- They must complete the online meeting evaluation form.
- They must pass the learning assessment test with at least 75% correct answers. Only one attempt is allowed.
The learning assessment test and meeting evaluation form must be submitted within three days of the event.
Please note that in order to access the learning assessment test, users must (A) register at the course venue and (B) submit the online meeting evaluation form.
Certificate of attendance
To download the certificate of attendance, users must have registered at the course venue.
If their attendance is less than 75% of the stated duration, the certificate will reflect the percentage of attendance.
We strongly encourage users to keep track of their personal badge and the badge recordings by the AccMed personnel, it is users' responsibility to have their attendance recorded accurately.
-
Training objective
Contenuti tecnico-professionali (conoscenze e competenze) specifici di ciascuna professione, di ciascuna specializzazione e di ciascuna attività ultraspecialistica, ivi incluse le malattie rare e la medicina di genere